BL-M07D1 for HER2-positive or HER2-low breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 75 (and likely have a disease stage that matches the study’s age limits), and sign consent.
- Have cancer that is HER2-positive or HER2-low, with confirmation by pathology, and that has failed standard treatment or no standard options are available.
- Have at least one measurable tumor spot on scans, and expect to live at least 3 months.
- Be well enough for treatment: performance status (ECOG) 0 or 1, and past treatment side effects have mostly recovered to low levels.
- Have enough “working” organs and blood counts (bone marrow, liver, and kidneys) and acceptable blood clotting tests.
- Be able to provide tumor tissue (archived or fresh) within 2 years, unless the study doctor decides it’s okay to proceed without tissue if other criteria fit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
This trial compares a new drug, BL-M07D1, to an existing treatment (DS-8201) for women with HR-positive, HER2-low breast cancer that has come back or spread. The goal is to see if the new drug works better or has fewer side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.